CARUGNO, ANDREA
 Distribuzione geografica
Continente #
AS - Asia 9.613
NA - Nord America 4.636
EU - Europa 3.597
SA - Sud America 1.051
AF - Africa 210
OC - Oceania 41
Continente sconosciuto - Info sul continente non disponibili 4
Totale 19.152
Nazione #
US - Stati Uniti d'America 4.411
VN - Vietnam 3.469
SG - Singapore 2.256
IT - Italia 1.355
CN - Cina 1.324
HK - Hong Kong 1.035
BR - Brasile 786
RU - Federazione Russa 627
IE - Irlanda 368
BD - Bangladesh 281
DE - Germania 276
KR - Corea 265
IN - India 226
FR - Francia 169
SE - Svezia 149
NL - Olanda 146
ID - Indonesia 145
GB - Regno Unito 141
CA - Canada 110
AR - Argentina 98
FI - Finlandia 77
IQ - Iraq 66
MX - Messico 64
PK - Pakistan 64
TR - Turchia 64
ZA - Sudafrica 58
ES - Italia 51
PH - Filippine 50
AT - Austria 49
JP - Giappone 48
MY - Malesia 41
SA - Arabia Saudita 41
UA - Ucraina 40
AU - Australia 34
CO - Colombia 34
MA - Marocco 33
TH - Thailandia 33
UZ - Uzbekistan 31
CL - Cile 29
EC - Ecuador 28
PL - Polonia 26
ET - Etiopia 22
IR - Iran 21
KE - Kenya 21
AE - Emirati Arabi Uniti 20
AF - Afghanistan, Repubblica islamica di 19
CH - Svizzera 19
UY - Uruguay 19
VE - Venezuela 18
JO - Giordania 17
TN - Tunisia 17
PY - Paraguay 16
NP - Nepal 15
PT - Portogallo 14
BO - Bolivia 13
AL - Albania 12
LT - Lituania 12
PA - Panama 12
RO - Romania 11
AZ - Azerbaigian 10
PE - Perù 10
EG - Egitto 9
IL - Israele 9
NG - Nigeria 9
BE - Belgio 8
CZ - Repubblica Ceca 8
DZ - Algeria 8
KZ - Kazakistan 8
OM - Oman 8
TW - Taiwan 8
CR - Costa Rica 7
JM - Giamaica 7
DO - Repubblica Dominicana 6
NZ - Nuova Zelanda 6
SY - Repubblica araba siriana 6
AO - Angola 5
BG - Bulgaria 5
CD - Congo 5
PS - Palestinian Territory 5
RS - Serbia 5
TT - Trinidad e Tobago 5
HR - Croazia 4
KG - Kirghizistan 4
LU - Lussemburgo 4
SN - Senegal 4
XK - ???statistics.table.value.countryCode.XK??? 4
YE - Yemen 4
GR - Grecia 3
HN - Honduras 3
KW - Kuwait 3
LB - Libano 3
LK - Sri Lanka 3
AM - Armenia 2
BB - Barbados 2
DK - Danimarca 2
EE - Estonia 2
GH - Ghana 2
GN - Guinea 2
GT - Guatemala 2
HU - Ungheria 2
Totale 19.108
Città #
Singapore 1.305
Ho Chi Minh City 1.091
Hong Kong 1.021
Hanoi 960
San Jose 753
Hefei 522
Ashburn 439
Dublin 355
New York 291
Milan 269
Seoul 260
Santa Clara 259
Los Angeles 168
Chicago 158
The Dalles 151
Chandler 148
Da Nang 130
Frankfurt am Main 128
Rome 106
Lauterbourg 102
Council Bluffs 97
Dallas 96
Beijing 95
Boardman 94
Jakarta 88
Haiphong 82
São Paulo 79
Quận Bình Thạnh 73
Buffalo 69
Biên Hòa 67
Moscow 67
Thái Nguyên 62
Ninh Bình 55
Ha Long 54
Vũng Tàu 51
Nuremberg 47
Helsinki 45
Hải Dương 43
West Jordan 40
Bắc Ninh 39
Can Tho 39
Quận Một 38
Naples 37
Rio de Janeiro 34
Bologna 33
Amsterdam 32
Bắc Giang 32
Orem 32
Baghdad 31
Quận Phú Nhuận 29
Tokyo 29
Toronto 29
Atlanta 26
Kent 26
Lappeenranta 26
Seattle 26
Shanghai 26
Tashkent 25
London 24
Munich 24
Turin 24
Vinh 24
Vĩnh Tường 24
Florence 23
Hòa Bình 23
Lang Son 23
Vienna 23
Montreal 22
Phủ Lý 22
Sydney 22
Warsaw 22
Bangkok 21
Chennai 21
Genoa 21
Lấp Vò 20
Mexico City 20
Phoenix 20
Brescia 19
Denver 19
Guangzhou 19
Houston 19
Quận Bảy 19
Dhaka 18
Lahore 18
Manila 18
Brooklyn 17
Jeddah 17
Johannesburg 17
Kuala Lumpur 17
Montevideo 17
Nairobi 17
Paris 17
Curitiba 16
Huizen 16
Belo Horizonte 15
Carate Brianza 15
Istanbul 15
Mumbai 15
Quảng Ninh 15
Quận Bốn 15
Totale 11.322
Nome #
Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021 1.615
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 578
Esperienza del centro di Bergamo 427
Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 419
Burden Clinico della Psoriasi Burden Psicologico della Psoriasi 399
Esposizione e discussione della casistica bergamasca 396
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 393
Epidemiological, Phenotypic, Histological, and Genetic Traits in Multiple and Familial Melanomas: a study of 333 cases 358
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 358
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 332
51042 Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma 322
Profilo super responder in corso di trattamento con bimekizumab: studio retrospettivo multicentrico nella psoriasi moderato-grave 294
Sfide terapeutiche ed esperienze a confronto 245
Addictive behavior and diseases in patients with chronic skin diseases: preliminary findings of a cross-sectional study in Europe 239
Melanoma in Adolescents and Young Adults (AYAs): An Italian Multi-Centric Retrospective Experience 238
Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management 237
Awareness of obesity among patients with psoriasis 229
Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study 225
Esposizione e discussione dell’esperienza del centro con focalizzazione sui temi controversi 222
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study 215
Ambulatori multidisciplinari 215
The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: A 16-week multicentre real-world experience - IL PSO (Italian Landscape Psoriasis) 204
Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma 201
Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients 201
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis) 197
Italian guidelines in diagnosis and treatment of alopecia areata 191
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis) 188
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis) 187
Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019 183
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma 183
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis) 179
Age-Related Variations in Clinical, Histological, and Genetic Characteristics in Multiple and Familial Melanomas: A Study of 333 Patients 174
Diagnostic Imaging of Agminated Blue Lesions and Blue Lesions with Satellitosis: Case Series with a Concise Review of the Current Literature 169
Thin Amelanotic and Hypomelanotic Melanoma: Clinicopathological and Dermoscopic Features 168
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis) 166
“Learning to fly”: quando la pratica supera la teoria. La casistica dei centri 165
HIV and mpox: evaluation of clinical course and outcomes from an international dermatologic registry 164
Monkeypox: an Italian, multicenter study of 104 cases 160
Italian Guidelines in patch testing - Adapted from the European Society of Contact Dermatitis (ESCD) 159
Monitoraggio epidemiologico di un corso di e-learning per medici di medicina generale all’interno del Melanoma Multimedia Education Programme 157
Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach 148
Clinical-epidemiological aspects of the Monkeypox 2022 epidemic: a multicenter study by the Italian SIDeMaST Group of Sexually Transmitted, Infectious and Tropical Diseases 147
Midline Anterior Neck Inclusion Cyst in a Pediatric Patient: A Case Report and Literature Review with a Dermatologic Perspective 146
Arrhythmias and other cardiovascular diseases in young patients (<40 years) with moderate/severe atopic dermatitis: A multicentric study in northern Italy 143
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 143
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study 142
Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals 140
A dermatologic assessment of 101 mpox (monkeypox) cases from 13 countries during the 2022 outbreak: Skin lesion morphology, clinical course, and scarring 140
Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study 139
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma 138
Epidemiological, Phenotypical, Histological and Genetic Characteristics of Patients with Multiple Melanomas: Study of 108 patients at ASST Papa Giovanni XXIII, Bergamo 138
Safety of anti-IL-23 risankizumab treatment in a patient with severe psoriasis and Charcot-Marie-Tooth disease 137
Adult-onset tufted angiomas associated with an arteriovenous malformation in a renal transplant recipient: Case report and review of the literature 136
Mycosis fungoides: Association of KIR ligands and HLA-DQB1∗05 with bad prognosis of the disease 135
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study 134
Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19) 134
Monkeypox nell’esperienza del gruppo MTS 133
Narrowband UVB phototherapy for pediatric generalized pityriasis lichenoides 132
COVID-19 and biologics for psoriasis: A high-epidemic area experience—Bergamo, Lombardy, Italy 132
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry 130
Italian guidelines for therapy of atopic dermatitis—Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) 129
Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience 129
The new Italian SIDAPA Baseline Series for patch testing (2023): an update according to the new regulatory pathway for contact allergens 128
Childhood Pemphigus Vulgaris during COVID-19 Outbreak Successfully Treated with Prednisone and Azathioprine: A Case Report and Literature Review 128
Trattamento della psoriasi in placche in soggetti con infezione da HIV con inibitori della IL-23: dati di efficacia e sicurezza nel medio-lungo termine 127
Hepatitis C infection in Italian psoriatic patients: Prevalence and correlation with patient age and psoriasis severity 126
Agreement on classification of clinical photographs of pigmentary lesions: Exercise after a training course with young dermatologists 124
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study 124
Use of anti Il-23 p19 inhibitors in cancer patients with severe psoriasis, a multicentric Italian experience 124
Patients with bullous skin disease in a high-epidemic COVID-19 area, Bergamo, Italy 124
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 122
Usefulness of in vivo photodiagnosis for the identification of tumor margins in recurrent basal cell carcinoma of the face 119
Coronavirus disease 2019 (COVID-19) rash in a psoriatic patient treated with Secukinumab: Is there a role for Interleukin 17? 118
RNAscope in situ hybridization and RT-PCR for detection of SARS-CoV-2 in chilblain-like lesions: A clinical, laboratory and histopathological study 117
Eruptive xanthomas after extensive tattooing: A case report and literature review 116
Histologic features of long-lasting chilblain-like lesions in a paediatric COVID-19 patient 116
Vasculitides with cutaneous expression in children: Clinico-pathological correlations 116
La diagnosi clinica, il ruolo del dermatologo 116
An unconventional case of scurvy 116
Mpox first skin lesion location: a reflection of mode of transmission? 116
Mpox in persons living with HIV: results from an international dermatologic registry 115
Efficacia e sicurezza dei farmaci anti IL 23 nel trattamento della psoriasi in placche in soggetti con infezione da HIV 114
Cutaneous blastic plasmacytoid dendritic cell neoplasm: Successful palliative treatment with oral prednisone in an elderly patient 111
Risk of acute postoperative hypertension after topical photodynamic therapy for non-melanoma skin cancer 110
Genetic telecounseling: evaluation of efficacy and outcomes through the Genetic Counseling Outcome Scale (GCOS) questionnaire in a cohort of patients with a suspected melanoma susceptibility syndrome 109
Pompholyx of the hands after intravenous immunoglobulin therapy for clinically isolated syndrome: A paediatric case 109
Artrite psoriasica ed early PsA Il paziente giovane/naive - casi clinici Il paziente sovrappeso/obeso - casi clinici Il paziente con comorbidità 108
IgA anti-epidermal transglutaminase autoantibodies: A simple test to improve differential diagnosis between dermatitis herpetiformis and atopic dermatitis 108
Rapid remission of atypical cutaneous lobular breast cancer metastases after aromatase inhibitor therapy: a case report and literature review 108
Patogenesi: cosa è utile sapere? 107
Specific IgE to Staphylococcus aureus superantigens in patients affected by bullous pemphigoid 107
IgA anti-epidermal transglutaminase autoantibodies: A sensible and sensitive marker for diagnosis of dermatitis herpetiformis in adult patients 107
La terapia topica 107
Factors associated with hospitalization due to COVID-19 in patients with psoriasis: insights from a global registry 106
Metronidazole-induced linear immunoglobulin A disease in a patient suffering from ulcerative colitis: a case report and focused review of the literature 105
Risankizumab: un nuovo modo di gestire la malattia psoriasica 102
Cutaneous lupus erythematosus patients in a high-epidemic COVID-19 area, Bergamo, Italy 102
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 101
No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy 101
Intralesional vinblastine injections for treatment of Classic Kaposi sarcoma in diabetic patients 101
Totale 18.692
Categoria #
all - tutte 61.352
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.352


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023880 0 176 73 29 83 131 150 72 74 16 54 22
2023/20241.655 44 52 51 38 120 414 235 75 134 130 176 186
2024/20256.230 250 471 413 274 351 212 405 152 359 576 432 2.335
2025/202610.902 2.179 1.447 666 965 825 419 1.529 396 680 771 440 585
Totale 19.667